581 results about "Heart failure" patented technology

The invention is applicable to the technical field of biological detection, provides a fluorescence immunochromatography detection method based on monatomic nano-enzyme enhancement, and particularly relates to two application forms: in the first form, a detection signal enhanced fluorescence immunochromatography detection card and a sample diluent containing a monatomic nano-enzyme are involved; in the second form, the invention relates to a fluorescence immunochromatography detection card with enhanced detection signals, and a sample pad of the detection card is obtained by soaking a sample pad treatment solution containing a monatomic nano-enzyme solution. The two application forms both relate to a monatomic nano-enzyme solution, and the solution is composed of monatomic nano-enzyme, bio-enzyme composite microspheres, a protective agent, a surfactant, a thickening agent and a preservative. The monatomic nano enzyme is composed of an atomic-scale dispersed metal active center and a carrier material. When the method is used for detecting myocardial and inflammatory markers, the limit of quantitation can reach the pg / mL level, the detection linear range can span three orders of magnitude, and the clinical examination use requirements can be met. The kit can be applied to rapid quantitative detection of myocardial and inflammatory markers, has the advantages of high sensitivity, rapidness, convenience and high efficiency, and provides an auxiliary diagnosis basis for early screening of myocardial infarction, heart failure and infection related diseases.

The exemplified methods and systems facilitate the quantification of cardiac cycle-variability as a metric of signal quality of an acquired signal data set and the rejection, based on that quantification, of said acquired signal data set from one or more subsequent analyses that can predict and / or estimate a metric associated with the presence, non-presence, severity, and / or localization of abnormal cardiovascular conditions or disease, including, for example, but not limited to, coronary artery disease, abnormal left ventricular end-diastolic pressure disease (LVEDP), pulmonary hypertension and subcategories thereof, heart failure (HF), among others as discussed herein. The quantification of levels of cycle-variability assessed noise such as skeletal-muscle-related-signal contamination and muscle-artifact-noise contamination, and other asynchronous-noise contamination in an acquired signal can be subsequently used for the automated rejection of such asynchronous noise from measurements of biophysical signals.

The invention relates to the technical field of active peptides, in particular to a myocardial active peptide capable of relieving heart failure and protecting heart and a preparation method thereof. The method takes pig hearts as raw materials, and sequentially comprises the following steps: pretreating the pig hearts, adding water, and homogenizing; adding alkaline protease to carry out first constant-temperature enzymolysis; adding neutral protease and flavourzyme to carry out second constant-temperature enzymolysis; then lipase is added for third-time constant-temperature enzymolysis, and enzyme deactivation and cooling are carried out; and finally, adding activated carbon into the enzymatic hydrolysate, filtering with diatomite, and spray-drying to obtain the myocardial active peptide. According to the method, the yield and the purity of the active peptide are remarkably improved through a synergistic process of three-step enzymolysis and activated carbon purification, the obtained product is rich in small molecule peptide with a definite heart protection function, and a new way is provided for high-value utilization of pig heart resources and development of functional products for preventing and treating heart failure.

The invention provides a non-invasive LVEF monitoring method and system based on millimeter wave radar chest displacement signals. The method comprises the steps that S1, millimeter wave radar signals are transmitted; s2, thoracic cavity micro-motion signals are collected; s3, preprocessing the thoracic cavity micro-motion signal; step S4, separating vital signs; s5, extracting heart failure features; step S6, risk assessment; and S7, outputting a result. According to the invention, a set of non-contact and continuous monitoring cardiac function evaluation system is constructed through creative combination of a radar sensing technology and medical diagnosis, and compared with a traditional LVEF detection method (such as echocardiography, cardiac MRI and the like), breakthrough improvement in clinical practicability, data continuity and technical universality is realized.

The invention discloses an intelligent rehabilitation monitoring method and device for a heart failure patient, and relates to the technical field of rehabilitation data processing.The method comprises the steps that on the basis of multiple collection time scales, monitoring item time sequence data sets are obtained, and the monitoring item time sequence data sets comprise the time sequence data set, corresponding to the multiple collection time scales, of each monitoring item; health feature value extraction is carried out on the time sequence data set of the monitoring items, and feature value sequences corresponding to different collection time scales are generated; constructing a multi-time-scale multivariate sequential sequence, and quantifying a physiological system elasticity coefficient value of the heart failure patient by using a preset event elasticity extraction mechanism; and inputting the multi-time-scale multivariate sequential sequence and the elastic coefficient value as monitoring features into a heart failure rehabilitation trajectory prediction model, outputting a health index sequence in a future intervention window, and performing elastic loss critical point identification as an early intervention point. Therefore, the accuracy and foresight of monitoring the rehabilitation health trend of the heart failure patient are improved.

The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and / or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).

The invention relates to the technical field of heart failure auxiliary diagnosis and treatment, in particular to a heart failure auxiliary diagnosis and treatment knowledge distillation method and system.The knowledge distillation method comprises the steps that an age-crossing fusion data set is built by combining ancient medical case text data related to traditional Chinese medicine heart failure; performing field fine tuning on the pre-training model to generate a basic teacher model; performing semantic alignment, and outputting a cross-time contrast database; constructing a curative effect scoring model by using the time sequence model, and outputting a quantitative association database; using a graph neural network to output an intelligent heart failure knowledge graph, and generating a comprehensive teacher model; performing knowledge distillation on the comprehensive teacher model to generate a clinical student model; the knowledge distillation system is applied to the knowledge distillation method, has a dynamic learning ability, can fuse ancient and modern trans-time knowledge and combine traditional Chinese medicine ancient book wisdom to carry out heart failure auxiliary diagnosis and treatment, and can give consideration to model performance and deployment efficiency through knowledge distillation.

The invention provides a heart failure risk prediction method and system based on multi-modal feature fusion, and the method comprises the steps: firstly carrying out the data feature analysis, carrying out the screening and extraction of data key features, and then building a multi-modal fusion model to provide more comprehensive and accurate medical data analysis. And finally, constructing a patient prognosis evaluation model so as to predict the heart failure risk of the heart failure patient. The heart failure key indexes are automatically screened through data feature analysis, then the multi-modal deep learning model is fused, the heart failure risk of the patient can be accurately predicted in advance, and especially in clinic, early intervention, individualized treatment and resource optimization can be achieved accordingly.

The invention relates to application of tsRNA-3025a as a prognostic marker of acute myocardial infarction and a treatment target spot of myocardial ischemia reperfusion injury. A DNA (Deoxyribonucleic Acid) sequence corresponding to the tsRNA-3025a is shown as SEQ ID NO: 1: 5 '-ATCCTGCCGACTACGCCA-3'. The tsRNA-3025a can be used for treating acute myocardial infarction and myocardial ischemia reperfusion injury. In the aspect of prognosis, a detection kit is provided, and the risk of heart failure and short-term adverse events of a patient is evaluated by quantitatively detecting the expression level of the tsRNA. In the aspect of treatment, the invention provides the application of the anti-tagomir for inhibiting the function or expression of tsRNA-3025a in the preparation of the medicine for treating the myocardial ischemia reperfusion injury, and the anti-tagomir is subjected to specific chemical modification. A novel biomarker is provided for prognosis risk stratification of acute myocardial infarction, and an effective treatment strategy is provided for prevention and treatment of myocardial ischemia-reperfusion injury.

Methods, systems, and devices for evaluating function of a heart are provided. The methods can include use of one or more imaging modalities to assess diastolic function. The methods, systems, and devices can employ various features of a cardiac volume curve to assess cardiac function. The methods, systems, and devices can be used to guide diagnosis, therapy, and / or training for sick or well patients. Methods, systems, and devices for assessing likelihood of hospital readmission for a heart failure patient are also provided.

The invention discloses a cardiovascular risk early warning method based on multi-modal time sequence data, relates to the technical field of medical health information monitoring, and aims to solve the problem of confusion of causes of dyspnea at night by constructing a cross-modal direction and time delay relation in a sliding time window. Phenotype similar phenomena such as pure blood oxygen reduction / wake-up are decomposed into a comparable time sequence interaction structure, so that a blocking chain type process and a non-blocking type heart failure related process can be distinguished on the structural level, and therefore false alarm and missing alarm caused by confusion are reduced. Meanwhile, a multi-channel signal is firstly converted into a time sequence causal diagram, and then in-window statistical characteristics are combined for judgment, so that the model not only utilizes the self change of each channel, but also utilizes the interaction evidence of the first and second channels, the influence direction and the delay length, and the expression ability of the pathophysiological chain difference is improved.

Provided herein is a method of using digital twins for medical diagnosis, prediction, and / or prognosis of a disease or condition, such as diagnosis, prediction, and / or prognosis of one or more cancers, organ-specific age prediction, predicting of female aging, predicting hospital-acquired infection, predicting dialysis time series, predicting diabetes and complications, predicting pregnancy and child outcome, predicting heart failure, predicting myopia, predicting vision in anti-VEGF treatment, or any combination thereof. A system and non-transitory computer-readable storage medium configured for performing the method is also disclosed.

The invention relates to the technical field of physiological signal processing, and discloses a millimeter wave radar multi-dimensional physiological feature decoupling heart failure early warning system and method, and the method comprises the steps: configuring a millimeter wave radar to transmit a dual-beam frequency modulation continuous wave signal, collecting human body reflection echoes, and generating a multi-channel original digital signal matrix; generating a chest region and acra region phase signal, an overall reflection signal amplitude sequence and an overall phase drift signal after spatial isolation enhancement through distance-Doppler combined processing; decoupling to obtain a beat-by-beat heartbeat interval sequence, a pulse wave transmission time sequence and a daily net body fluid variation sequence; obtaining a rule engine risk level and a machine learning early warning sign, and determining a final risk assessment level through fusion decision; synchronous high-precision collection and decoupling of non-contact multi-dimensional physiological parameters are achieved, and accuracy and specificity of heart failure decompensation early warning are improved through double-layer model fusion.

The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and / or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g., neurosurgery, endovascular clot removal, spinal tap, aneurysm repair, or deep brain stimulation, as well as retinal edema), as well as hyponatremia and excess fluid retention, and diseases such as epilepsy, retinal ischemia and other diseases of the eye associated with abnormalities in intraocular pressure and / or tissue hydration, myocardial ischemia, myocardial ischemia / reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines, as well as to novel assays for identifying aquaporin inhibitors.

Interatrial shunts having incorporated physiologic sensors are provided for monitoring and treating cardiovascular syndromes, including heart failure and pulmonary hypertension, in which the one or more sensors are affixed to the shunt to measure a physiologic parameter within the interatrial shunt. The one or more sensors may be directly affixed to or within a lumenal surface of the shunt or may be disposed on a support structure in a spaced relation to the shunt lumen, the one or more sensors disposed at locations subject to little or no pannus formation or cardiac wall motion artifact.

The invention relates to compounds of Formula (I), or pharmaceutically acceptable salts thereof; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of Formula (I) may be useful as therapeutic and / or preventative agents to treat diseases that involve abnormal amino acid metabolism, amino acid transport and / or amino acid level, cardiovascular disorders, renal disorders, or metabolic diseases, such as phenylketonuria, NASH, NAFLD, heart failure, chronic kidney disease, and related disorders.

The invention provides an application of a CGRP inhibitor in preparation of a medicine for treating myocardial infarction or heart failure, relates to the technical field of biomedicine, and has the technical key points that the invention provides the CGRP inhibitor Rimegepant and provides an effect of the CGRP inhibitor Rimegepant in myocardial infarction and heart failure, and the CGRP inhibitor Rimegepant can be used for preparing a medicine for treating myocardial infarction or heart failure. The myocardial infarction and / or heart failure model is constructed through left anterior descending branch coronary artery ligation. In-vitro experiments verify that the expression of the CGRP receptor protein in the heart of a mouse after heart failure is increased, and prove that the CGRP inhibitor Rimegeant can effectively inhibit the expression of the CGRP receptor protein, and further research is carried out, so that a potential treatment strategy is provided for drug research and development. The in-heart CGRP receptor inhibitor can obviously relieve the myocardial infarction and / or heart failure course of mice, and down-regulate the protein expression of the CGRP receptor at the same time.

The present disclosure relates treating skeletal muscle weakness associated with heart failure by administering a compound that binds to leaky ryanodine receptors (RyRs). Compounds of the present disclosure can bind to and repair the leak in both RyR1 and RyR2 to improve skeletal muscle and cardiac function, respectively.

The application discloses a fish scale protein polypeptide anti-chronic heart failure efficacy evaluation system, relates to the technical field of biological active polypeptide evaluation and cardiovascular disease function analysis, and comprises a raw material processing module for preparing fish scale protein polypeptides, a CHF model construction module for animal experiments, a function detection module, and a data processing and analysis module. Multidimensional statistics and visual algorithm are adopted to integrate tissue remodeling indexes such as heart function, oxidative stress and inflammatory reaction, so that comprehensive evaluation of the efficacy of fish scale protein polypeptides is realized. The application can realize systematic, quantitative and mechanistic evaluation of the anti-chronic heart failure effect of fish scale protein polypeptides, solve the problems of single evaluation index, poor repeatability of results and lack of mechanism correlation in the prior art, and has the advantages of comprehensive evaluation, reliable results, wide application range and strong generalizability.

The invention relates to the field of deep learning, and discloses a heart failure patient home care intelligent monitoring method combined with deep learning, which comprises the following steps: continuously acquiring the heart rate, blood pressure, breathing and body movement states of a patient in a home environment; performing conjoint analysis of time and activity states on the data streams after priority sorting, and forming a dynamic health feature set in combination with historical health records of patients and environment variable information; comprehensively evaluating the dynamic health feature set by using a deep learning model, and identifying a potential abnormal mode of short-time change through the deep learning model; marking and grouping the physiological parameters and related behavior scenes corresponding to the candidate abnormal events, locally evaluating the current health state of the patient based on grouping information, and identifying a potential high-risk condition; and according to the local evaluation result and the overall health trend of the patient, generating real-time early warning and personalized nursing suggestions. The method has the advantage of improving the identification capability of short-time abnormity.

The present invention provides, in part, a novel small molecule PHD inhibitor having a structure according to Formula (A) or a sub-formula thereof: or a pharmaceutically acceptable salt thereof. The compounds provided herein are useful in the treatment of diseases, including heart diseases (e.g., ischemic heart disease, congestive heart failure, and valvular heart disease), lung diseases (e.g., acute lung injury, pulmonary arterial hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), liver diseases (e.g., acute liver failure and liver fibrosis, and cirrhosis), and kidney diseases (e.g., acute liver failure, liver fibrosis, and cirrhosis). Acute kidney injury and chronic kidney disease).

A lung sound analysis system includes a storage means for storing therein the history of auscultation observations on lung sound data of each of auscultation positions of a subject who is a heart failure patient, a calculation means for calculating appearance frequency of abnormal sounds for each of the auscultation positions on the basis of the history, a determination means for determining the sequence of the auscultation positions at which lung sounds are to be auscultated from the subject, on the basis of the calculated appearance frequency, and an acquisition means for giving guidance on the auscultation positions of the subject to an operator according to the determined sequence, and acquiring time-series acoustic signals including lung sounds from a guided auscultation position. The system supports medical decision-making for healthcare professionals monitoring heart failure patients.

The invention discloses a preparation method of yang-strengthening heart-strengthening decoction for improving the treatment efficacy of moderate and severe heart failure, and belongs to the field of traditional Chinese medicine preparation. The method aims at solving the problems that an existing traditional Chinese medicine prescription is not strict in safety control, unstable in quality and the like. The preparation method comprises the following steps: weighing the following medicinal materials in parts by weight: black prepared aconite root, ginseng and the like, and carrying out special pretreatment of soaking and decocting the monarch drug black prepared aconite root so as to remarkably reduce the toxicity of the black prepared aconite root; combining the pretreated black prepared common monkshood daughter root with other medicinal materials, decocting, and filtering to obtain an extracting solution; preparing the extracting solution into a dry extract by adopting a vacuum concentration and drying process and introducing key quality control indexes such as relative density and water content; and finally, preparing the dried extract into modern solid preparations such as granules or capsules and the like. According to the invention, through source toxicity reduction and process quantitative control, the safety of the product and the uniformity of batch-to-batch quality are ensured, meanwhile, the dosage form is optimized, and the convenience and compliance of medication of patients are improved. The invention further discloses a process flow diagram of the preparation method.

To provide a method of treating a patient with chronic heart failure using a medicament comprising neuregulin.SOLUTION: A companion diagnostic test is first performed on each patient prior to treatment, and the appropriate treatment is provided to each patient according to the companion diagnostic test results. If the test results are within a preferred therapeutic range for treatment, the patient is suitable for treatment of heart failure by administration of an effective amount of neuregulin.SELECTED DRAWING: None

A lung sound analysis system includes a storage means for storing therein the history of auscultation observations on lung sound data of each of auscultation positions of a subject who is a heart failure patient, a calculation means for calculating appearance frequency of abnormal sounds for each of the auscultation positions on the basis of the history, a determination means for determining the sequence of the auscultation positions at which lung sounds are to be auscultated from the subject, on the basis of the calculated appearance frequency, and an acquisition means for giving guidance on the auscultation positions of the subject to an operator according to the determined sequence, and acquiring time-series acoustic signals including lung sounds from a guided auscultation position. The system supports medical decision-making for healthcare professionals monitoring heart failure patients.

The present invention provides, in part, novel small molecule inhibitors of PHD, having a structure according to Formula (I), and sub-formulas thereof: Formula (I) or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for treatment or prevention of diseases including heart (e.g. ischemic heart disease, congestive heart failure, and valvular heart disease), lung (e.g., lung inflammation, pneumonia, acute lung injury, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), respiratory (e.g.,respiratory infection, acute respiratory distress syndrome), liver (e.g. acute liver failure and liver fibrosis and cirrhosis), and kidney (e.g. acute kidney injury and chronic kidney disease) disease, inflammatory bowel disease (IBD), ischemic reperfusion injury (e.g., stroke), retinopathy of prematurity (ROP), bronchopulmonary dysplasia (BPD), and white matter injury (WMI).

This invention relates to a method and system for cardiovascular disease risk assessment based on machine learning models. By utilizing machine learning models to focus on predicting the risk of heart failure, it accurately distinguishes between healthy individuals and those with cardiovascular disease, emphasizing the differentiation of heart failure and other common cardiovascular diseases, and deeply exploring diagnostic indicators, thus opening new avenues for cardiovascular diagnosis and treatment. It hierarchically utilizes features closely related to blood cells, blood lipids, and blood glucose, and constructs predictive models using multiple machine learning models, laying a solid foundation for further in-depth research. This invention fully utilizes diagnostic indicators and multiple machine learning models, making full use of the predictive results and differentiated characteristics of different machine learning models to achieve efficient and accurate 5-category risk assessment.

Methods of administering an anti-arrhythmic, such as dofetilide, to a patient in an amount effective for treating a cardiovascular condition are described. The drug can be administered intravenously for at least one hour. A loading dose of 0.1 to 12 μg / kg bodyweight over a duration of up to 60 minutes can be administered and / or a maintenance dose of 0.1 to 10 μg / kg / hr can be administered intravenously over a duration of at least 1 hour, optionally alternatively or in addition wherein the amount of the loading dose and / or the IV maintenance dose is in the range of about ±50% of a maintenance dofetilide dose. The cardiovascular condition can include atrial fibrillation or flutter, ventricular tachycardia, hemodynamically stable or unstable ventricular tachycardia, paroxysmal atrial fibrillation, ventricular fibrillation, paroxysmal supraventricular tachycardia, heart failure, coronary artery disease, or pulmonary artery hypertension. A patient's QT interval and / or a creatinine clearance can be measured, and the effective amount can be selected based on either or both of the QT interval or the creatinine clearance measurements.

The invention relates to the technical field of biological medicines, in particular to application of a monoclonal antibody in medicines for treating heart diseases related to Alzheimer's disease. According to the application disclosed by the invention, the application range of the lencanamazumab is expanded to prevention and treatment of AD-accompanied heart failure and pathological myocardial remodeling, and a new drug strategy is provided for treatment of patients with AD-associated heart failure or pathological myocardial remodeling.

The invention discloses preparation and application of a therapeutic drug for preventing and treating heart failure or myocardial ischemia-reperfusion injury. Research results of the invention show that the exosome secreted by kidney cells after stimulation and induction of the drug-containing serum of Zhenwu decoction has a myocardial protection effect. Therefore, the invention provides a novel candidate drug for heart failure or myocardial ischemia-reperfusion injury.